SION News
Archived Headlines
- Cystic fibrosis biotech Sionna Therapeutics sets terms for $150 million IPO 02/03/25
- US IPO Week Ahead: Cement carve-out leads the IPO calendar as more gear up to launch 01/31/25
- Sizable IPO filings reach a three-year high amid steady stream of deals 01/30/25
- US IPO Weekly Recap: Oil and gas well equipment provider Flowco debuts, while more sizable deals join the pipeline 01/17/25
- Cystic fibrosis biotech Sionna Therapeutics files for a $100 million IPO 01/17/25
Renaissance Capital's February IPO Market Update
Eighteen IPOs raised a combined $2.8 billion in February, well above the 10-year historical average (12 IPOs, $2.1B). Micro-caps dominated deal flow, but five issuers completed offerings of $100 million or more, led by SailPoint (SAIL), which raised $1.4...read more
Bigger Biotechs: IPO valuations have soared for drug developers over the past decade
New biotech issuers have doubled in size over the past decade. Last year, the average biotech IPO went public at a market cap of $644 million, compared to $318 million a decade earlier, for deals raising at least $20 million. The average wasn’t skewed by ...read more
US IPO Weekly Recap: Cement and cystic fibrosis drugs lead a 6 IPO week
Two sizable companies and a handful of small Asian issuers listed in the US this past week. Titan America (TTAM), the US business unit of Titan Cement, priced slightly below the midpoint to raise $384 million at a $2.9 billion market cap. Operating primarily ...read more
Cystic fibrosis biotech Sionna Therapeutics prices upsized IPO at $18, the high end of the range
Sionna Therapeutics, a Phase 1 biotech developing novel therapies for cystic fibrosis, raised $191 million by offering 10.6 million shares at $18, the high end of the range of $16 to $18. The company offered 1.8 million more shares than anticipated. Sionna is...read more